An emerging leader in the immunotherapy space, we are advancing a pre-clinical pipeline of therapeutic candidates intended to elicit broad and durable anti-tumor and anti-viral responses and cure disease.
SEC Filings
U.S. Securities and Exchange Commission filings
View SEC Filings
Investor Contact
Indaptus Management
Indaptus Board of Directors
Press Releases
Annual Meeting
Corporate Governance
Events and Presentations
Sept 12, 2022
24th Annual H.C. Wainwright Global Investment Conference | Webcast Link
June 16, 2022
JMP Securities Life Sciences Conference | Webcast Link
June 8 – 10, 2022
Jefferies Healthcare Conference | Webcast Link
May 23 – 26, 2022
H.C. Wainwright Global Investment Conference | Webcast Link
March 28 – 30, 2022
2022 Virtual Growth Conference | Webcast Link
March 14 – 15, 2022
34th Annual ROTH Conference | Webcast Link
January 10, 2022 at 7AM ET
H.C. Wainwright BioConnect 2022 Virtual Conference | Webcast Link
Documents
September 2022